We are live on ! Find out more
AMRI

Albany Molecular Research Inc
AMRI

Delisted

AMRI was delisted on the 31st of August, 2017.

132 hedge funds and large institutions have $548M invested in Albany Molecular Research Inc in 2014 Q2 according to their latest regulatory filings, with 40 funds opening new positions, 33 increasing their positions, 42 reducing their positions, and 21 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,061% more call options, than puts

Call options by funds: $6.77M | Put options by funds: $583K

90% more first-time investments, than exits

New positions opened: 40 | Existing positions closed: 21

17% more funds holding

Funds holding: 113132 (+19)

6% more capital invested

Capital invested by funds: $515M → $548M (+$32.2M)

0% more funds holding in top 10

Funds holding in top 10: 22 (0)

21% less repeat investments, than reductions

Existing positions increased: 33 | Existing positions reduced: 42

Holders
132
Holders Change
+19
Holders Change %
+16.81%
% of All Funds
3.79%
Holding in Top 10
2
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.06%
New
40
Increased
33
Reduced
42
Closed
21
Calls
$6.77M
Puts
$583K
Net Calls
+$6.19M
Net Calls Change
+$2.55M
Name Holding Trade Value Shares
Change
Change in
Stake
FWM
126
Focused Wealth Management
New York
$7K
Federated Hermes
127
Federated Hermes
Pennsylvania
$7K +$6.25K +369 New
Citigroup
128
Citigroup
New York
$6K -$171K -10,077 -97%
NFG
129
Next Financial Group
Texas
$5K +$4.23K +250 New
GC
130
Globeflex Capital
California
$3K -$627 -37 -17%
GAM
131
Gemmer Asset Management
California
$1K +$542 +32 New
BNP Paribas Financial Markets
132
BNP Paribas Financial Markets
France
$604 +$508 +30 New
BIM
133
Bogle Investment Management
Massachusetts
-$9.74M -523,914 Closed
American Century Companies
134
American Century Companies
Missouri
-$3.55M -191,179 Closed
CBOA
135
Commonwealth Bank of Australia
Australia
-$3.05M -164,062 Closed
PCM
136
Piermont Capital Management
Missouri
-$2.79M -150,330 Closed
AI
137
Analytic Investors
California
-$1.92M -103,083 Closed
Axa
138
Axa
France
-$1.03M -55,600 Closed
CCM
139
Cadence Capital Management
Massachusetts
-$931K -50,060 Closed
SFM
140
Soros Fund Management
New York
-$905K -48,700 Closed
FM
141
Forward Management
California
-$717K -48,560 Closed
GCP
142
GSA Capital Partners
United Kingdom
-$760K -40,903 Closed
LCS
143
Levin Capital Strategies
New York
-$597K -32,115 Closed
TC
144
TFS Capital
Pennsylvania
-$521K -28,045 Closed
SCA
145
SAC Capital Advisors
Connecticut
-$472K -25,400 Closed
LPL Financial
146
LPL Financial
California
-$339K -18,230 Closed
SKK
147
Shepherd Kaplan Krochuk
Massachusetts
-$308K -16,570 Closed
OSAM
148
O'Shaughnessy Asset Management
Connecticut
-$281K -15,161 Closed
Verition Fund Management
149
Verition Fund Management
Connecticut
-$267K -14,359 Closed
GMIM
150
General Motors Investment Management
New York
-$247K -13,289 Closed

AMRI Hedge Fund Activity: Q2 2014 in Review

132 of the 3,479 institutional investors tracked by Wall St. Rank reported a position in Albany Molecular Research Inc (AMRI) for Q2 2014, worth a combined $548M — up 6.3% from $515M a quarter earlier.

Buyers outnumbered sellers: 40 funds opened new AMRI positions and 21 closed out — a net gain of 19 holders — while 33 added to existing stakes and 42 trimmed.

The largest buyer was Permian Investment Partners, opening a new position worth an estimated $11.4M. The largest seller was Visium Asset Management, cutting an estimated $16.6M.

  • 132 institutional investors held Albany Molecular Research Inc (AMRI) as of Q2 2014, up from 113 in Q1 2014.
  • Funds reported $548M of Albany Molecular Research Inc stock for Q2 2014, up 6.3% quarter-over-quarter.
  • 40 funds opened new Albany Molecular Research Inc positions in Q2 2014 and 21 closed out, a net change of +19 holders.
  • The largest Albany Molecular Research Inc buyer in Q2 2014 was Permian Investment Partners, an estimated $11.4M added.
  • The largest Albany Molecular Research Inc seller in Q2 2014 was Visium Asset Management, an estimated $16.6M sold.

Based on aggregated 13F filings for Q2 2014.